AstraZeneca and Daiichi Sankyo announced positive data from a registrational Phase 3 study of Datroway, a next-generation drug succeeding Enhertu, in triple-negative breast cancer (TNBC). This breakthrough could lead to a key label expansion for Datroway, strengthening its position in a challenging subtype of breast cancer. The development represents significant progress in targeted therapies addressing TNBC, a form with limited treatment options.